Perfusion-guided gene therapy for improving cancer treatment
AssigneesBoard of Regents, The University of Texas System, The University of Chicago
InventorsShashank R. Sirsi, Aditi Bellary, Chance Nowak, Leonidas Bleris, Sonia L. Hernandez
Life of this patent
Estimating the term…
Abstract
The present methods use gene therapy to confer inducible nitric oxide synthase (iNOS) expression solely in the tumor space, using focused ultrasound targeting. NOS catalyzes the reaction that generates nitric oxide (NO), a potent endogenous vasodilator. Microbubble-mediated non-viral delivery overcomes major barriers associated with non-viral NO gene therapy. The methods increase tumor perfusion and compound the efficacy of a vast array of chemotherapy, radiotherapy, and immune-based treatments.
Claims10
A method for administering a therapeutic agent to a tumor in a subject, comprising:
- loading iNOS-expressing plasmid DNA into microbubbles to produce loaded microbubbles;
- infusing the loaded microbubbles into a space surrounding the tumor in the subject;
- applying image-guided focused ultrasound to the tumor, whereby the iNOS-expressing plasmid DNA is delivered selectively into the tumor through sonopermeation, whereby iNOS is selectively expressed in the tumor, and whereby nitric oxide levels in the tumor increase;
- allowing perfusion of the tumor to increase over a period of time as a result of increased nitric oxide levels;
- and
- administering a therapeutic agent to the space surrounding the tumor in the subject, whereby uptake of the therapeutic agent into the tumor occurs.
A method for treating neuroblastoma in a subject, comprising:
- loading iNOS-expressing plasmid DNA into microbubbles to produce loaded microbubbles;
- infusing the loaded microbubbles into a space surrounding a tumor in the subject, wherein the tumor is caused by neuroblastoma;
- applying image-guided focused ultrasound to the tumor, whereby the iNOS-expressing plasmid DNA is delivered selectively into the tumor through sonopermeation, whereby iNOS is selectively expressed in the tumor, and whereby nitric oxide levels in the tumor increase;
- allowing perfusion of the tumor to increase over a period of time as a result of increased nitric oxide levels;
- monitoring perfusion rate of the tumor using longitudinal quantitative contrast-enhanced ultrasound imaging to identify an optimal time for administering the therapeutic agent, wherein the longitudinal quantitative contrast-enhanced ultrasound imaging visualizes circulation of microbubbles in blood vessels of the tumor and the space surrounding the tumor in the subject, and wherein the optimal time for administering the therapeutic agent is a time when the tumor perfusion rate is increased;
- loading a liposome-encapsulated chemotherapy drug into microbubbles to produce therapeutic loaded microbubbles;
- infusing the therapeutic loaded microbubbles into the space surrounding the tumor in the subject;
- and
- applying image-guided focused ultrasound to the tumor, whereby the liposome-encapsulated chemotherapy drug is delivered selectively into the tumor through sonopermeation, and whereby the liposome-encapsulated chemotherapy drug increases apoptosis in the tumor and treats the neuroblastoma in the subject.
Dependencies are inferred from the claim text.